EGFR and triple-negative breast carcinoma: The strongest associations were observed with Sapitinib, an inhibitor of ErbB1/2/359, Osimertinib, a lung cancer EGFR inhibitor, and Acetalax, a drug used in the treatment of triple-negative breast cancers.